Septerna (NASDAQ:SEPN) Rating Lowered to “Equal Weight” at Wells Fargo & Company

Septerna (NASDAQ:SEPN) was downgraded by stock analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. They currently have a $14.00 price target on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 8.02% from the company’s previous close.

Several other equities analysts have also issued reports on the company. TD Cowen started coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $50.00 price target on shares of Septerna in a research report on Tuesday, February 11th.

Septerna Stock Up 12.2 %

Shares of Septerna stock opened at $12.96 on Tuesday. The firm’s fifty day moving average price is $19.15. Septerna has a 12 month low of $10.34 and a 12 month high of $28.99.

Hedge Funds Weigh In On Septerna

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC purchased a new position in Septerna in the 4th quarter worth about $25,000. New York State Common Retirement Fund purchased a new position in Septerna in the 4th quarter worth about $32,000. Legal & General Group Plc purchased a new position in Septerna in the 4th quarter worth about $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna in the 4th quarter worth about $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Septerna in the 4th quarter worth about $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.